TGFBR3

Transforming Growth Factor Beta Receptor III (TGFBR3), also known as betaglycan, is a type of protein that in humans is encoded by the TGFBR3 gene. It is a component of the cell membrane and acts as a co-receptor in the transforming growth factor beta (TGF-β) signaling pathway. This pathway plays a critical role in regulating cell growth, cell differentiation, embryonic development, and immune system responses. TGFBR3 has been implicated in various biological processes and diseases, including cancer, cardiovascular diseases, and fibrosis.

Function

TGFBR3 is a membrane proteoglycan that presents ligands to the TGF-β receptors, TGFBR1 and TGFBR2, thereby facilitating ligand-receptor interactions and enhancing the response to TGF-β. Unlike TGFBR1 and TGFBR2, which are serine/threonine kinase receptors, TGFBR3 does not have intrinsic kinase activity. Instead, it modulates the signaling pathway by binding to TGF-β ligands and presenting them to the signaling receptors, acting as a reservoir for these ligands on the cell surface.

Structure

The TGFBR3 protein is characterized by a large extracellular domain, a single transmembrane domain, and a short cytoplasmic domain. The extracellular domain is responsible for ligand binding, while the cytoplasmic domain interacts with other proteins within the cell to mediate signal transduction.

Clinical Significance

Alterations in TGFBR3 expression or function have been associated with several pathological conditions. In cancer, TGFBR3 can have dual roles, acting as a tumor suppressor in early stages of tumor development by inhibiting cell proliferation and promoting apoptosis, and as a promoter of tumor progression and metastasis in later stages by enhancing cell migration and invasion. The loss of TGFBR3 expression has been observed in various types of cancer, including breast, prostate, and pancreatic cancers.

In cardiovascular diseases, TGFBR3 has been implicated in the regulation of vascular development and the pathogenesis of atherosclerosis. Its role in fibrosis involves the regulation of extracellular matrix production and the modulation of fibroblast activity.

Genetics

The TGFBR3 gene is located on human chromosome 1q41. Mutations in this gene have been studied in the context of their association with diseases, although such mutations are relatively rare. The gene's regulation is complex and involves various transcription factors and epigenetic mechanisms.

Therapeutic Implications

Given its role in TGF-β signaling and disease pathogenesis, TGFBR3 is considered a potential therapeutic target. Strategies to modulate TGFBR3 activity include the use of monoclonal antibodies, small molecule inhibitors, and gene therapy approaches. These therapies aim to restore normal TGFBR3 function in diseases where it is dysregulated.

See Also

• Transforming growth factor beta
• TGF-beta signaling pathway
• Cell signaling
• Protein kinase

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian